ADDITIONAL RESOURCES: Video, hard copy requests, contact information and more available at: http://www.prnewswire.com/broadcast/23534/consumer.html NEW YORK, November 17 /PRNewswire/ -- THIS IS A MULTIVU REPORT BROUGHT TO YOU BY GENENTECH. THE FDA HAS JUST APPROVED HERCEPTIN, AS PART OF A TREATMENT REGIMEN CONTAINING DOXORUBICIN, CYCLOPHOSPHAMIDE, AND PACLITAXEL, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH HER2-POSITIVE NODE-POSITIVE BREAST CANCER. DR. EDWARD H. ROMOND IS PROFESSOR OF MEDICINE, DIVISION OF HEMATOLOGY AND ONCOLOGY AT THE UNIVERSITY OF KENTUCKY: "I think that the FDA approval for Herceptin for women with early stage her2-positive breast cancer is an extremely important and major step forward for women who have this disease." HER2-POSITIVE BREAST CANCER IS PARTICULARLY AGGRESSIVE AND OCCURS IN APPROXIMATELY 25 PERCENT OF WOMEN WITH BREAST CANCER. HERCEPTIN ADMINISTRATION CAN RESULT IN LEFT VENTRICULAR DYSFUNCTION AND CONGESTIVE HEART FAILURE. SERIOUS INFUSION REACTIONS AND PULMONARY TOXICITY HAVE OCCURRED; RARELY THESE HAVE BEEN FATAL. FOR MORE INFORMATION ON HERCEPTIN OR HER2-POSITIVE BREAST CANCER, PATIENTS SHOULD TALK TO THEIR DOCTOR OR VISIT HERCEPTIN.COM. I'M DANIELLE ADDAIR. HERCEPTIN SAFETY INFORMATION : Herceptin administration can result in left ventricular dysfunction and congestive heart failure (CHF). The incidence and severity of left ventricular cardiac dysfunction/CHF were highest in patients who received Herceptin concurrently with anthracycline-containing chemotherapy regimens. Herceptin should be discontinued in patients receiving adjuvant therapy for breast cancer who develop a clinically significant decrease in left ventricular function. In patients with metastatic breast cancer who develop a clinically significant decrease in left ventricular function, discontinuation of Herceptin should strongly be considered. Serious infusion reactions and pulmonary toxicity have occurred; rarely these have been fatal. Discontinuation of Herceptin should be strongly considered for infusion reactions manifesting as anaphylaxis, angioedema, pneumonitis, or acute respiratory distress syndrome. Exacerbation of chemotherapy-induced neutropenia has also occurred. The most common adverse reactions associated with Herceptin use were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, and myalgia. AUDIO PROVIDED BY: Genentech http://www.prnewswire.com/broadcast/23534/consumer.htmlDATASOURCE: Genentech CONTACT: FOR STORY INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313, EXT. 3 OR EMAIL Web site: http://www.herceptin.com/

Copyright